Cargando…

Genetic variability in cisplatin metabolic pathways and outcome of locally advanced head and neck squamous cell carcinoma patients

Advanced head and neck squamous cell carcinoma (HNSCC) patients have been treated with cisplatin (CDDP) chemoradiation, and the variability of treatment effects has been attributed to single nucleotide variants (SNVs) in genes of metabolic pathways. This study investigated the roles of GSTM1, GSTT1,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ferreira, Ana Maria Castro, Altemani, João Maurício Carrasco, Macedo, Ligia Traldi, Lourenço, Gustavo Jacob, Lima, Carmen Silvia Passos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10556039/ https://www.ncbi.nlm.nih.gov/pubmed/37798436 http://dx.doi.org/10.1038/s41598-023-44040-7

Ejemplares similares

Association of Clinical Aspects and Genetic Variants with the Severity of Cisplatin-Induced Ototoxicity in Head and Neck Squamous Cell Carcinoma: A Prospective Cohort Study
por: Macedo, Ligia Traldi, et al.
Publicado: (2023)

Polymorphisms in DNA mismatch repair pathway genes predict toxicity and response to cisplatin chemoradiation in head and neck squamous cell carcinoma patients
por: Nogueira, Guilherme Augusto Silva, et al.
Publicado: (2018)

Cost-minimization analysis of GSTP1c.313A>G genotyping for the prevention of cisplatin-induced nausea and vomiting: A Bayesian inference approach
por: Macedo, Ligia Traldi, et al.
Publicado: (2019)

XPD c.934G>A polymorphism of nucleotide excision repair pathway in outcome of head and neck squamous cell carcinoma patients treated with cisplatin chemoradiation
por: Lopes-Aguiar, Leisa, et al.
Publicado: (2016)

GSTM1, GSTT1 and GSTP1 Ile105Val polymorphisms in outcomes of head and neck squamous cell carcinoma patients treated with cisplatin chemoradiation
por: Pincinato, Eder C., et al.
Publicado: (2019)

Free three-dimensional image software in local extension assessment of oral squamous cell carcinoma: a pilot study
por: Gomes, João Pedro Perez, et al.
Publicado: (2022)

Do Genetic Polymorphisms Modulate Response Rate and Toxicity of Cisplatin Associated With Radiotherapy in Laryngeal Squamous Cell Carcinoma?: A Case Report
por: Lopes-Aguiar, Leisa, et al.
Publicado: (2015)

Decitabine Rescues Cisplatin Resistance in Head and Neck Squamous Cell Carcinoma
por: Viet, Chi T., et al.
Publicado: (2014)

Feasibility of concomitant cisplatin with hypofractionated radiotherapy for locally advanced head and neck squamous cell carcinoma
por: Jacinto, Alexandre Arthur, et al.
Publicado: (2018)

Data Normalization of Urine miRNA Profiling from Head and Neck Cancer Patients Treated with Cisplatin
por: Torso, Nadine de Godoy, et al.
Publicado: (2023)

Adverse drug reactions and kinetics of cisplatin excretion in urine of patients undergoing cisplatin chemotherapy and radiotherapy for head and neck cancer: a prospective study
por: Visacri, Marília Berlofa, et al.
Publicado: (2017)

Metoclopramide enhances the effect of cisplatin on xenografted squamous cell carcinoma of the head and neck.
por: KjellÃ©n, E., et al.
Publicado: (1989)

Mechanisms of Cisplatin Resistance in HPV Negative Head and Neck Squamous Cell Carcinomas
por: Griso, Ana Belén, et al.
Publicado: (2022)

Chemoradiation with Cisplatin vs. Carboplatin for Squamous Cell Carcinoma of the Head and Neck (SCCHN)
por: Rades, Dirk, et al.
Publicado: (2023)

Three-Dimensional Volume Imaging to Increase the Accuracy of Surgical Management in a Case of Recurrent Chordoma of the Clivus
por: Gomes, João Pedro Perez, et al.
Publicado: (2018)

MicroRNA-21 induces cisplatin resistance in head and neck squamous cell carcinoma
por: Sheng, Shuyan, et al.
Publicado: (2022)

Eligibility criteria to cisplatin in head and neck squamous cell carcinoma: Egyptian expert opinion
por: Abdulla, Mohamed, et al.
Publicado: (2023)

Transcriptomic and Proteomic Profiles for Elucidating Cisplatin Resistance in Head-and-Neck Squamous Cell Carcinoma
por: Garcia-Mayea, Yoelsis, et al.
Publicado: (2022)

Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck Unsuitable to Receive Cisplatin-Based Therapy
por: Porceddu, Sandro V., et al.
Publicado: (2020)

Genomic profile of a squamous cell carcinoma ex pleomorphic adenoma compared to a head and neck squamous cell carcinoma()
por: Mariano, Fernanda Viviane, et al.
Publicado: (2016)

Evaluation of the quality of life of patients before treatment of squamous cell carcinoma of the head and neck by means of chemoradiotherapy
por: Visacri, Marília Berlofa, et al.
Publicado: (2015)

DNA-Bound Platinum Is the Major Determinant of Cisplatin Sensitivity in Head and Neck Squamous Carcinoma Cells
por: Martens-de Kemp, Sanne R., et al.
Publicado: (2013)

Feasibility of Cisplatin/5-Fluorouracil and Panitumumab in Japanese Patients with Squamous Cell Carcinoma of the Head and Neck
por: Tahara, Makoto, et al.
Publicado: (2014)

Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck
por: Trieu, Vanessa, et al.
Publicado: (2018)

SLC23A2-05 (rs4987219) and KRAS-LCS6 (rs61764370) polymorphisms in patients with squamous cell carcinoma of the head and neck
por: SANTIAGO, MARÍLIA BUENO, et al.
Publicado: (2014)

Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups
por: Macedo, Ligia Traldi, et al.
Publicado: (2012)

Cisplatin, Cetuximab, and Radiation in Locally Advanced Head and Neck Squamous Cell Cancer: A Retrospective Review
por: Peddi, Prakash, et al.
Publicado: (2015)

Appropriate Sequence for Afatinib and Cisplatin Combination Improves Anticancer Activity in Head and Neck Squamous Cell Carcinoma
por: Longton, Eleonore, et al.
Publicado: (2018)

Over-expression of BAG-1 in head and neck squamous cell carcinomas (HNSCC) is associated with cisplatin-resistance
por: Liu, Shutong, et al.
Publicado: (2017)

Regulation of cisplatin-resistant head and neck squamous cell carcinoma by the SRC/ETS-1 signaling pathway
por: Yang, Zejia, et al.
Publicado: (2019)

Efficacy and safety of cisplatin and weekly docetaxel in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
por: Kim, Moon Jin, et al.
Publicado: (2019)

Concurrent Chemoradiotherapy With Weekly Low-Dose Cisplatin for Japanese Patients With Head and Neck Squamous Cell Carcinoma
por: Shinohara, Shogo, et al.
Publicado: (2021)

Pseudogene Transcripts in Head and Neck Cancer: Literature Review and In Silico Analysis
por: Carron, Juliana, et al.
Publicado: (2021)

Genetic variability & chemotoxicity of 5-fluorouracil & cisplatin in head & neck cancer patients: a preliminary study
por: Dhawan, Dipali, et al.
Publicado: (2013)

Radiotherapy potentiation with weekly cisplatin compared to standard every 3 weeks cisplatin chemotherapy for locoregionally advanced head and neck squamous cell carcinoma
por: Fayette, Jérôme, et al.
Publicado: (2015)

Postoperative adjuvant radiochemotherapy with cisplatin versus adjuvant radiochemotherapy with cisplatin and pembrolizumab in locally advanced head and neck squamous cell carcinoma- the study protocol of the Adrisk trial
por: Wiegand, Susanne, et al.
Publicado: (2023)

Chemoradiotherapy With Generic Cisplatin Formulations for Head and Neck Cancers
por: Shimada, Rie, et al.
Publicado: (2018)

Synergistic antitumor effect of AAV-mediated TRAIL expression combined with cisplatin on head and neck squamous cell carcinoma
por: Jiang, Minghong, et al.
Publicado: (2011)

NM23-H1 expression of head and neck squamous cell carcinoma in association with the response to cisplatin treatment
por: Wang, Yi-Fen, et al.
Publicado: (2014)

S-nitrosoglutathione-mediated STAT3 regulation in efficacy of radiotherapy and cisplatin therapy in head and neck squamous cell carcinoma()
por: Kaliyaperumal, Kolanjiappan, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ob698i7rgkempt11esb6nri9ef